Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas

PLUS THERAPEUTICS, INC.

2025-Q2 EPS reported -$0.50 revenue$2,449,000

Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.
CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.
REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.
Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-108854
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2025-08-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:43.327659+00:00
generated_at: 2026-05-17T12:45:17.245219+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-108854
json_url: https://secwatch.observer/filing/0000950170-25-108854.json
markdown_url: https://secwatch.observer/filing/0000950170-25-108854.md
text_url: https://secwatch.observer/filing/0000950170-25-108854.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/0000950170-25-108854-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000095017025108854/pstv-20250814.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-108854

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.